Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nazilai
- Development stage
- Phase 2
- Lead developer
- Xinjiang Technical Institute of Physics and Chemistry, Chinese Academy of Sciences
- Administration
- Oral
01
Overview
Nazilai is a traditional Uyghur herbal medicine formulated as granules for the treatment of the common cold. Specifically targeting "heat-type" Nazilai (热性乃孜来) symptoms in Uyghur medical theory, the drug is being developed by the Xinjiang Institute of Ecology and Geography of the Chinese Academy of Sciences. It is currently undergoing Phase II clinical evaluation in China to assess its efficacy and safety in alleviating symptoms of upper respiratory tract infections in adults.
- Other names
- Nazilai granulesRexing Nazilai热性乃孜来
Beyond the preview
Go deeper on Nazilai.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nazilai.